Farmas USA

yo te dejo al amigo bastardo, ya os sabeis todo lo que dice, pero esto es lo que comenta él sobre 2017
https://www.thestreet.com/story/13939672/2/17-thoughts-on-biotech-stocks-to-kick-off-2017.html

Futuros USA vienen hoy bien fuertes

ITEK

Cagada estrepitosa de fase III. Funciona peror que el placebo.

http://www.businesswire.com/news/home/20170103005518/en/

CLVS

Colocación
initiates a $175M public offering of common stock. Price, volume and terms have yet to be announced. Net proceeds will fund general corporate purposes including the U.S. launch of Rubraca
http://seekingalpha.com/news/3233033-clovis-readies-equity-offering

KITE

Nueva IND for KITE-718, an Investigational Next Generation T-Cell Receptor (TCR) Therapy Targeting Cancer Antigens MAGE A3 & MAGE A6

ABEO

Fármaco huérfano UE Juvenile Batten Disease

http://finance.yahoo.com/news/abeona-therapeutics-receives-orphan-drug-124300793.html?soc_src=social

PixarBio to take over InVivo Therapeutics in all-stock deal
http://seekingalpha.com/news/3233078-pixarbio-take-invivo-therapeutics-stock-deal

De momento se deja algo más del 3% en pre-market.

NVIV PXRB

Sin que sirve de precedente, me gusta el argumento contra-intuitivo del punto #4...

"Biotech investor sentiment: It sucks. That's actually bullish because basically anything positive is upside at this point."

Leyendo el PR de PixarBio, entiendo que es una OPA hostil del ex-CEO de InVivo...

1.- En la web de InVivo no sé recoge la oferta.
2.- El PR pega una bonita rajada del board y CEO actuales.

https://pixarbio.com/time-make-us-pharma-great-combining-two-frank-reynolds-founded-pharmas-pixarbio-corp-otcqxpxrb-invivo-therapeutics-nasdaqnviv-77000000-stock-offe/

"It’s been over 3.5 years since I resigned as CEO of InVivo Therapeutics Corporation, to found PixarBio Corporation (PXRB) in August 2013. It’s clear that 2013-2017 have not been great years for the NVIV CEO & the NVIV Board of Directors. The round of recent MAJOR exits makes it a perfect time to keep the required exits for success going. It’s time to focus on shareholder value, and REAL change at NVIV. I founded InVivo Therapeutics over 11 years ago but the last 3.5 years have been a black hole for investor’s money, and the NVIV team has had a real dead spot in innovation failing in the area of shareholder value creation, so it’s time for real change", said PixarBio CEO Frank Reynolds.

NVIV PXRB

Juan, me incorporo 5 min tarde a la primera sesión del año y no paro de ver lechugas por todas partes ...Había ganas, eh!

ouch, como escuece empezar el año viendo desde la barrera un +5 a la que mas ganas le tenias .. HZNP :(